Business
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration Canad...
About this update from Aurora Cannabis Inc.
[{"type":"text","content":"\n\n\n\n Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n Collaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platform\n \n\n\n\n Following successful launch of CBD lozenge, the collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in\n \n Canada\n \n\n\n\n\n\n EDMONTON, AB\n \n , and\n \n STAMFORD, Conn.\n \n\n ,\n \n\n Aug. 1, 2024\n \n\n /CNW/ - Aurora Cannabis Inc. (\"\n \n Aurora\n \n \") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce that Aurora has entered into a commercial collaboration with Cogent International Manufacturing Ltd. (\"\n \n Cogent\n \n \"), a wholly-owned subsidiary of Vectura Fertin Pharma Inc. Through this arrangement, Cogent will initially launch its newly developed CBD lozenge on Aurora's Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis. Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in\n \n Canada\n \n .\n \n\n\n\n\n\n\n\n\n \"We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in\n \n Canada\n \n to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma's new CBD lozenge,\" said\n \n Miguel Martin\n \n , CEO for Aurora. \"As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased inte...